178 related articles for article (PubMed ID: 38030811)
21. Upregulation of mesothelial genes in ovarian carcinoma cells is associated with an unfavorable clinical outcome and the promotion of cancer cell adhesion.
Ojasalu K; Brehm C; Hartung K; Nischak M; Finkernagel F; Rexin P; Nist A; Pavlakis E; Stiewe T; Jansen JM; Wagner U; Gattenlöhner S; Bräuninger A; Müller-Brüsselbach S; Reinartz S; Müller R
Mol Oncol; 2020 Sep; 14(9):2142-2162. PubMed ID: 32533757
[TBL] [Abstract][Full Text] [Related]
22. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
23. PAX8 modulates the tumor microenvironment of high grade serous ovarian cancer through changes in the secretome.
Salvi A; Hardy LR; Heath KN; Watry S; Pergande MR; Cologna SM; Burdette JE
Neoplasia; 2023 Feb; 36():100866. PubMed ID: 36586182
[TBL] [Abstract][Full Text] [Related]
24. Low levels of IGFBP7 expression in high-grade serous ovarian carcinoma is associated with patient outcome.
Gambaro K; Quinn MC; Cáceres-Gorriti KY; Shapiro RS; Provencher D; Rahimi K; Mes-Masson AM; Tonin PN
BMC Cancer; 2015 Mar; 15():135. PubMed ID: 25886299
[TBL] [Abstract][Full Text] [Related]
25. Aldehyde dehydrogenase 1/epidermal growth factor receptor coexpression is characteristic of a highly aggressive, poor-prognosis subgroup of high-grade serous ovarian carcinoma.
Liebscher CA; Prinzler J; Sinn BV; Budczies J; Denkert C; Noske A; Sehouli J; Braicu EI; Dietel M; Darb-Esfahani S
Hum Pathol; 2013 Aug; 44(8):1465-71. PubMed ID: 23465277
[TBL] [Abstract][Full Text] [Related]
26. The fallopian tube as the origin of high grade serous ovarian cancer: review of a paradigm shift.
Reade CJ; McVey RM; Tone AA; Finlayson SJ; McAlpine JN; Fung-Kee-Fung M; Ferguson SE
J Obstet Gynaecol Can; 2014 Feb; 36(2):133-140. PubMed ID: 24518912
[TBL] [Abstract][Full Text] [Related]
27. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
28. Sequential molecular changes and dynamic oxidative stress in high-grade serous ovarian carcinogenesis.
Kobayashi H; Ogawa K; Kawahara N; Iwai K; Niiro E; Morioka S; Yamada Y
Free Radic Res; 2017 Oct; 51(9-10):755-764. PubMed ID: 28931330
[TBL] [Abstract][Full Text] [Related]
29. YAP induces high-grade serous carcinoma in fallopian tube secretory epithelial cells.
Hua G; Lv X; He C; Remmenga SW; Rodabough KJ; Dong J; Yang L; Lele SM; Yang P; Zhou J; Karst A; Drapkin RI; Davis JS; Wang C
Oncogene; 2016 Apr; 35(17):2247-65. PubMed ID: 26364602
[TBL] [Abstract][Full Text] [Related]
30. Proteomics of High-Grade Serous Ovarian Cancer Models Identifies Cancer-Associated Fibroblast Markers Associated with Clinical Outcomes.
Govindarajan M; Ignatchenko V; Ailles L; Kislinger T
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671461
[TBL] [Abstract][Full Text] [Related]
31. Deep Metabolomics of a High-Grade Serous Ovarian Cancer Triple-Knockout Mouse Model.
Huang D; Gaul DA; Nan H; Kim J; Fernández FM
J Proteome Res; 2019 Aug; 18(8):3184-3194. PubMed ID: 31290664
[TBL] [Abstract][Full Text] [Related]
32. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
33. The 14-3-3σ protein promotes HCC anoikis resistance by inhibiting EGFR degradation and thereby activating the EGFR-dependent ERK1/2 signaling pathway.
Song J; Liu Y; Liu F; Zhang L; Li G; Yuan C; Yu C; Lu X; Liu Q; Chen X; Liang H; Ding Z; Zhang B
Theranostics; 2021; 11(3):996-1015. PubMed ID: 33391517
[TBL] [Abstract][Full Text] [Related]
34. Dual-platform affinity proteomics identifies links between the recurrence of ovarian carcinoma and proteins released into the tumor microenvironment.
Finkernagel F; Reinartz S; Schuldner M; Malz A; Jansen JM; Wagner U; Worzfeld T; Graumann J; von Strandmann EP; Müller R
Theranostics; 2019; 9(22):6601-6617. PubMed ID: 31588238
[TBL] [Abstract][Full Text] [Related]
35. [Clinicopathological study of SET subtype of ovarian high-grade serous carcinoma].
Sun YW; Shen DH; Cui SS; He HJ; Zhang XL; Wang W; Liu CR
Zhonghua Fu Chan Ke Za Zhi; 2019 Sep; 54(9):595-600. PubMed ID: 31550775
[No Abstract] [Full Text] [Related]
36. WNT signaling inducing activity in ascites predicts poor outcome in ovarian cancer.
Kotrbová A; Ovesná P; Gybel' T; Radaszkiewicz T; Bednaříková M; Hausnerová J; Jandáková E; Minář L; Crha I; Weinberger V; Záveský L; Bryja V; Pospíchalová V
Theranostics; 2020; 10(2):537-552. PubMed ID: 31903136
[TBL] [Abstract][Full Text] [Related]
37. ROR2 induces cell apoptosis via activating IRE1α/JNK/CHOP pathway in high-grade serous ovarian carcinoma in vitro and in vivo.
Li R; Liu T; Shi J; Luan W; Wei X; Yu J; Mao H; Liu P
J Transl Med; 2019 Dec; 17(1):428. PubMed ID: 31878941
[TBL] [Abstract][Full Text] [Related]
38. Downregulation of HtrA1 promotes resistance to anoikis and peritoneal dissemination of ovarian cancer cells.
He X; Ota T; Liu P; Su C; Chien J; Shridhar V
Cancer Res; 2010 Apr; 70(8):3109-18. PubMed ID: 20388781
[TBL] [Abstract][Full Text] [Related]
39. Insulin-like growth factor (IGF) and hepatocyte growth factor (HGF) in follicular fluid cooperatively promote the oncogenesis of high-grade serous carcinoma from fallopian tube epithelial cells: Dissection of the molecular effects.
Chu TY; Khine AA; Wu NY; Chen PC; Chu SC; Lee MH; Huang HS
Mol Carcinog; 2023 Sep; 62(9):1417-1427. PubMed ID: 37265438
[TBL] [Abstract][Full Text] [Related]
40. Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin.
Park JT; Chen X; Tropè CG; Davidson B; Shih IeM; Wang TL
Am J Pathol; 2010 Sep; 177(3):1087-94. PubMed ID: 20671266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]